NIH SBIR Direct-to-Phase II (Omnibus)
Funds United States small businesses moving directly into major development when early biomedical feasibility is already established.
The NIH SBIR Direct-to-Phase II (D2PII) Omnibus allows U.S. small businesses to apply directly for Phase II-level funding without a prior NIH Phase I award, provided the company can demonstrate that Phase I-equivalent feasibility has already been established through other means. Issued under activity code R44 as a "New" application (not a renewal), D2PII awards carry the same cap as standard Phase…
Phase II-scope biomedical R&D for projects whose feasibility has been established through prior non-SBIR work (e.g. university research, foundation funding, internal R&D).
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up
Guides for this application
All guides →SBIR/STTR Grants for Deeptech Startups
A practical guide to SBIR and STTR grants for deeptech startups, including agency fit, Phase I and II logic, eligibility, budgets, and review criteria.
DocumentsNIH Biosketch Guide: Format, SciENcv Steps, and Examples
Learn what an NIH biosketch is, how the format works, what to prepare for SciENcv, and how startup teams should avoid common biosketch mistakes.
Write proposalHow to Write a Specific Aims Page
Learn how to write a specific aims page for NIH, SBIR-adjacent, and translational R&D grants, with structure, reviewer logic, examples, and common mistakes.
Where to applyGrants for Biotech Startups: NIH, NSF, SBIR/STTR, and Non-Dilutive Funding
A practical guide to grants for biotech startups, including NIH SBIR/STTR, NSF, translational funding, evidence, regulatory readiness, and budgets.
More from NIH
All grants from this funder →Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI)
🇺🇸NIH · United States
Funds the design and early validation of frameworks — guidelines, protocols and standard procedures — for building and deploying multimodal medical AI reliably.
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers
🇺🇸NIH · United States
Funds a clinical centre inside a consortium testing how to use anti-obesity medication in children without harming their growth or mental health.
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center
🇺🇸NIH · United States
Funds the single centre that runs statistics, data and coordination for the consortium testing anti-obesity medication in children.
Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs)
🇺🇸NIH · United States
Funds work on the methodological problems that make trials of rapid-acting psychotropic drugs hard to interpret, and on sustaining the treatment afterwards.
Assay Validation of High Quality Markers for Clinical Studies in Cancer
🇺🇸NIH · United States
Funds two years of analytical validation then three of clinical validation for a cancer biomarker assay that already works on human samples.
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3)
🇺🇸NIH · United States
Funds the clinical validation of a cancer biomarker assay whose analytical performance has already been proven.
Similar grants
Browse the directory →
NIH SBIR Phase II
🇺🇸NIH SEED · United States
Supports United States biomedical small businesses advancing successful feasibility work into scale-up development.
NSF SBIR Phase II
🇺🇸NSF · United States
Funds United States deep-tech startups extending proven early projects into substantial technology development.
NEI SBIR Phase II — R&D
🇺🇸NEI · United States
Supports United States. small businesses scaling vision concepts into full development pathways.
NCATS SBIR Phase II
🇺🇸NCATS · United States
Backs small businesses scaling proven translational findings into applied solutions and early market readiness.
NCI SBIR/STTR Omnibus (Next Receipt 5)
🇺🇸NCI · United States
Supports small businesses developing cancer technologies through national NIH collaboration pathways.
NEI STTR Phase II — R&D
🇺🇸NEI · United States
Funds collaborative small-business partnerships to mature vision innovation into market-ready healthcare technologies.